{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:35:02Z","timestamp":1775122502750,"version":"3.50.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The growing incidence and lethality of pancreatic cancer urges the development of new therapeutic approaches. Anti-tumoral vaccines can potentiate the immune response against the tumor, targeting specific antigens expressed only on tumor cells. In this work, we designed new vaccines for pancreatic cancer, composed by chitosan nanocapsules (CS NCs) containing imiquimod (IMQ) as adjuvant, and targeting the K-Ras mutation G12V.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental design<\/jats:title><jats:p>We tested the immunogenicity of our vaccines in mice, carrying different combinations of K-Ras mutated peptides. Then, we analyzed their prophylactic and therapeutic efficacy in mice bearing heterotopic pancreatic cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Unexpectedly, although good results were observed at short time points, the different combinations of our CS NCs vaccines seemed to potentiate tumor growth and reduce survival rate. We propose that this effect could be due to an inadequate immune response, partially because of the induction of a regulatory tolerogenic response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results call for caution in the use of some NCs containing IMQ in the immunotherapy against pancreatic cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1153724","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T04:26:55Z","timestamp":1681273615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunization with nanovaccines containing mutated K-Ras peptides and imiquimod aggravates heterotopic pancreatic cancer induced in mice"],"prefix":"10.3389","volume":"14","author":[{"given":"Amparo","family":"Mart\u00ednez-P\u00e9rez","sequence":"first","affiliation":[]},{"given":"Lara","family":"Diego-Gonz\u00e1lez","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Vilanova","sequence":"additional","affiliation":[]},{"given":"Alexandra","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Rosana","family":"Sim\u00f3n-V\u00e1zquez","sequence":"additional","affiliation":[]},{"given":"\u00c1frica","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: Opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: The first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14760584.2020.1733420","article-title":"Cancer vaccines: Targeting KRAS-driven cancers","volume":"19","author":"Zhang","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"113914","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.09.012","article-title":"Co-Delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy","volume":"172","author":"Vicente","year":"2013","journal-title":"J Controlled Release"},{"key":"B10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics12060489","article-title":"Design of polymeric nanocapsules for intranasal vaccination against mycobacterium tuberculosis: Influence of the polymeric shell and antigen positioning","volume":"12","author":"Diego-Gonz\u00e1lez","year":"2020","journal-title":"Pharmaceutics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.04.013","article-title":"Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma","volume":"203","author":"Sciullo","year":"2019","journal-title":"Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0113","article-title":"Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant- specific induction of immunosuppressive cells","volume":"18","author":"Dang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.05.011","article-title":"Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence","volume":"19","author":"Guerra","year":"2011","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.025","article-title":"Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines","volume":"172","author":"Dobrovolskaia","year":"2013","journal-title":"J Controlled Release"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00100","article-title":"Chitosan nanoparticles: Shedding light on immunotoxicity and hemocompatibility","volume":"8","author":"Jesus","year":"2020","journal-title":"Front Bioengineering Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8282","DOI":"10.1038\/s41598-021-87720-y","article-title":"Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures","volume":"11","author":"Takiguchi","year":"2021","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.06.027","article-title":"Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis c","volume":"27","author":"Wedemeyer","year":"2009","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/nnm-2019-0206","article-title":"Design of polymeric nanocapsules to improve their lympho-targeting capacity","volume":"13","author":"Crecente-Campo","year":"2019","journal-title":"Nanomedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.94845","article-title":"The global burden of pancreatic cancer","volume":"16","author":"Lippi","year":"2020","journal-title":"Arch Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.12.014","article-title":"Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice","volume":"127","author":"Kim","year":"2008","journal-title":"J Controlled Release"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2016.08.050","article-title":"Characterization and anti-proliferative activity of curcumin loaded chitosan nanoparticles in cervical cancer","volume":"93","author":"Khan","year":"2016","journal-title":"Int J Biol Macromolecules"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2019.1577876","article-title":"Chitosan nanoparticles induced the antitumor effect in hepatocellular carcinoma cells by regulating ROS-mediated mitochondrial damage and endoplasmic reticulum stress","volume":"47","author":"Jiang","year":"2019","journal-title":"Artif Cells Nanom Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1997.1224","article-title":"Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations","volume":"182","author":"Abrams","year":"1997","journal-title":"Cell Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1998.tb05462.x","article-title":"Mutated ras peptides as vaccines in immunotherapy of cancer","volume":"74","author":"Gjertsen","year":"1998","journal-title":"Vox Sanguinis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction - the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12205","article-title":"Prevention strategies of mother-to-Child transmission of hepatitis b virus (HBV) infection","volume":"4","author":"Hu","year":"2020","journal-title":"Pediatr Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.11.1945","article-title":"Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein","volume":"191","author":"Siegel","year":"2000","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.176.4031.170","article-title":"The immune reaction as a stimulator of tumor growth","volume":"176","author":"Prehn","year":"1972","journal-title":"Science"},{"key":"B32","article-title":"Stimulatory effects of immune reactions upon the growths of untransplanted tumors","volume":"54","author":"Prehn","year":"1994","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1479-5876-12-55","article-title":"The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors","volume":"12","author":"Rahma","year":"2014","journal-title":"J Trans Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731947","article-title":"Regulatory T cells in autoimmunity and cancer: A duplicitous lifestyle","volume":"12","author":"Hatzioannou","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"\u201cIncreased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-391858-1.00007-1","article-title":"Chitosan-based nanoparticles as a hepatitis b antigen delivery system","volume":"509","author":"Lebre","year":"2012","journal-title":"Methods Enzymol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2016.2228","article-title":"Functional chitosan nanoparticles in cancer treatment","volume":"12","author":"Fu","year":"2016","journal-title":"J Biomed Nanotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2015.08.038","article-title":"Dual drug loaded chitosan nanoparticles-Sugar-Coated arsenal against pancreatic cancer","volume":"135","author":"David","year":"2015","journal-title":"Colloids Surfaces B: Biointerfaces"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2016.25","article-title":"Evaluation of anti-metastatic effect of chitosan nanoparticles on esophageal cancer-associated fibroblasts","volume":"2","author":"Potdar","year":"2016","journal-title":"J Cancer Metastasis Treat"},{"key":"B42","doi-asserted-by":"publisher","first-page":"45751","DOI":"10.1038\/srep45751","article-title":"Chitosan promotes cancer progression and stem cell properties in association with wnt signaling in colon and hepatocellular carcinoma cells","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12935-019-1027-3","article-title":"Role of the complement system in the tumor microenvironment","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/ijms22031109","article-title":"The Chitosan\/Agarose\/Nanoha bone scaffold-induced M2 macrophage polarization and its effect on osteogenic differentiation in vitro","volume":"22","author":"Kazimierczak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.09.012","article-title":"Macrophage polarization following chitosan implantation","volume":"34","author":"Vasconcelos","year":"2013","journal-title":"Biomaterials"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.37326","article-title":"Macrophage polarization in vitro and in vivo modified by contact with fragmented chitosan hydrogel","volume":"110","author":"Boxberg","year":"2022","journal-title":"J Biomed Materials Res - Part A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: From biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126257","article-title":"Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial","volume":"47","author":"Salasche","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.8829","article-title":"Treatment of locally recurrent mucosal melanoma with topical imiquimod","volume":"29","author":"Smyth","year":"2011","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejpb.2019.01.001","article-title":"Imiquimod-loaded nanocapsules improve cytotoxicity in cervical cancer cell line","volume":"136","author":"Frank","year":"2019","journal-title":"Eur J Pharmaceutics Biopharmaceutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1153724\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T04:26:58Z","timestamp":1681273618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1153724\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2023.1153724"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1153724","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"article-number":"1153724"}}